Clinical Trial News
Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome
Prota Therapeutics' long-term peanut allergy study published in Allergy confirms clinical remission as the optimal treatment outcome, with high-dose oral immunotherapies PRT120 and PRT100 showing lasting benefits, including improved quality of life and reduced allergic reactions.
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Therapeutics announces positive FDA feedback for amezalpat (TPST-1120) in treating first-line hepatocellular carcinoma, with agreement on Phase 3 study design and endpoints.
FDA Approves Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
FDA approves Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host disease (GVHD) after failure of at least two prior therapies in adult and pediatric patients weighing at least 40 kg.
Related Clinical Trials:
FDA Grants Accelerated Approval for Livdelzi (seladelpar) for the Treatment of Primary Biliary Cholangitis
FDA grants accelerated approval for Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC) in adults, either with ursodeoxycholic acid (UDCA) for inadequate response or as monotherapy for those unable to tolerate UDCA. The approval is based on a Phase 3 study showing 62% of Livdelzi-treated participants achieved a composite biochemical response at month 12, compared to 20% on placebo. Livdelzi led to ALP normalization in 25% of participants, a significant reduction in pruritus, and no treatment-related serious adverse events.
First Clinical Trial of ‘Paradoxical Intervention’ for Cancer to Begin Soon
A new approach to cancer therapy involves stressing tumor cells with an activator, LB-100, then eliminating them with a WEE1 inhibitor, adavosertib. This 'paradoxical intervention' worked well in mice and is set for a phase 1b clinical trial for advanced colorectal cancer.
Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer
Accutar Biotechnology receives FDA Fast Track designation for AC699 in ER+/HER2- breast cancer. AC699, an AI-enabled drug, targets ESR1-mutated advanced or metastatic breast cancer, showing a 50% objective response rate in Phase 1 trials.
Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials
An experimental malaria vaccine, tested in Malian adults, showed sustained protection against parasite infection and clinical malaria over two years without a booster dose. It also significantly protected women from malaria during pregnancy, suggesting potential for improved prevention strategies.
Related Clinical Trials:
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. submitted the NDA for UGN-102 (mitomycin) for intravesical solution, aiming to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The NDA is supported by the Phase 3 ENVISION study, which showed a 79.6% complete response rate at three months and an 82.3% 12-month duration of response. UroGen anticipates FDA approval in early 2025, potentially offering an alternative to repeated surgeries.
Enrollment Completed for the SAD Part 1 of Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals completed enrollment for Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment, with 45 participants in 5 cohorts. The trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726. Top-line data from the trial's SAD Part 1 is expected in Q3 2024, and from MAD Part 2 in Q1 2025. DA-1726 showed superior weight loss in pre-clinical data compared to other drugs, potentially positioning it as a best-in-class obesity drug.
FDA Approves Nemluvio (nemolizumab) for the Treatment of Adult Patients with Prurigo Nodularis
FDA approves Nemluvio (nemolizumab) for treating adult patients with prurigo nodularis, based on positive results from the phase III OLYMPIA trials, demonstrating significant improvements in itch and skin nodules.